Sandoz Settles Generic Drug Allegations for $195 Million

Sandoz has agreed to pay $195 million to settle charges related to the Department of Justice’s three-year antitrust investigation into the generic drug industry.

The DOJ charged the company in the U.S. District Court for the Eastern District of Pennsylvania of taking part in four conspiracies with other generic drugmakers between 2013 and 2015.

Sandoz admitted to conspiring with four companies including Rising Pharmaceuticals. The DOJ did not identify the three others. The conspiracy with Rising was for allocating customers and fixing prices for benazepril HCTZ. Rising already entered into a deferred prosecution agreement for its participation.